Preeclampsia Diagnostics Market to Surpass US$ 2,780.4 Million at a CAGR of 11.8% by 2028 | Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd

The growing prevalence of preeclampsia is a prime factor propelling the growth of the global preeclampsia diagnostics market. For instance, according to the World Health Organization (WHO), the prevalence of preeclampsia is seven times higher in the emerging countries as compared to the developed countries. Also, as per a report by BioMed Central (BMC) in 2019, the incidence of preeclampsia ranges from 1.8% to 16.7% in the developing economies. It affects around 10% of pregnant women in the African continent every year.

Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/4606

Global Preeclampsia Diagnostics Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic has drastically affected clinical trials. Many trials have paused enrollment and researchers are facing multiple challenges associated with setting up remote visits, and performing laboratory and other study assessments. According to a survey conducted by Medidata Solutions, Inc. (a U.S.-based technology company, which develops and markets software as a service for clinical trials), on April 23, 2020, 63% of survey respondents reported that they stopped recruiting new patients for ongoing clinical trials and 43% of the respondents have postponed their studies. The U.S. Food and Drug Administration (FDA) released guidelines on conducting clinical trials of medical products during the COVID-19 public health emergency in March 2020. The guidelines were further updated on July 02, 2020. The guidelines issued by the U.S. Food and Drug Administration (FDA) include general considerations to assist sponsors and researchers, which ensure the safety of trial participants, and compliance with good clinical practice (GCP) for the duration of the COVID-19 public health emergency.

Additionally, key companies operating are focusing on regulatory approvals for preeclampsia is again expected to support growth of the global preeclampsia diagnostics market. For instance, in June 2020, PerkinElmer received CE mark for its DELFIA Xpress sFlt-1 pre-eclampsia diagnostic kit. The blood test is designed for pregnant women in the second and third trimester. It measures the ratio of soluble Fms-like tyrosine-kinase-1 (sFlt-1). Abnormally high levels of the sFlt-1 protein have been linked to pre-eclampsia.

Key Takeaways of the Global Preeclampsia Diagnostics Market:

• The global preeclampsia diagnostics market is expected to exhibit a CAGR of 11.8% during the forecast period owing to growing research and development activities to introduce new tests for detecting biomarkers indicating preeclampsia, which is projected to boost the market. For instance, in July 2020, researchers from the University of Helsinki have showed that HLA-G gene regulates male-to-female ratio at birth. The study strengthens earlier findings of the vulnerability of male fetuses to preeclampsia
• Among end user, diagnostic centers segment accounted for the largest market share in the global preeclampsia diagnostics market over the forecast period. Growing prevalence of preeclampsia is projected to augment the segment growth over the forecast period. For instance, according to an article published in Medscape in 2018, it is clinically defined by hypertension and proteinuria, with or without pathologic edema. The incidence of preeclampsia in the U.S. is estimated to range from 2% to 6% in healthy, nulliparous women. Among all cases of the preeclampsia, 10% occur in pregnancies of less than 34 weeks’ gestation.
• Among regions, North America accounted for the largest market share in the global preeclampsia diagnostics market over the forecast period. Growing prevalence of preeclampsia is increasing medical treatment cost among women with preeclampsia and their newborns, which is projected to foster the segment growth over the forecast period. For instance, according to the American Journal of Obstetrics and Gynecology (AJOG) in 2017, increasing the chance of adverse health outcomes, preeclampsia accounts for over US $2.18 billion of health care expenditure in the first 12 months after birth.
• Major players operating in the global preeclampsia diagnostics market are Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG INSTRUMENTS GMBH, Metabolomic Diagnostics Ltd., Sera Prognostics, MOMM Diagnostics, Miraculins Inc.

Buy This Complete Business Report @ https://www.coherentmarketinsights.com/insight/buy-now/4606

Reasons to buy this Preeclampsia Diagnostics Market Report

☑ It attempts an analysis of the competing scenario.

☑ The current and exceptional product revenue market.

☑ An in-depth data on the regional investigation and competitive landscape structure.

☑ It benefits in creating an awareness of the important key product segments.

☑ The marketing strategies, opportunities, and development factors are explained.

☑ Preeclampsia Diagnostics market size estimation and recent advancements in the industry are explained.

The Study Objectives are:

✔ A comprehensive insight into key players operating in the Preeclampsia Diagnostics Market and their corresponding data.
✔ It includes product portfolio, annual revenue, expenditure on research and development, geographical presence, key developments in recent years, and growth strategies.
✔ Regional analysis, which includes insight into the dominant market and corresponding market share.
✔ It also includes various socio-economic factors affecting the evolution of the market in the region.
✔ The report offers a comprehensive insight into different individuals from value chains such as raw materials suppliers, distributors, and stockholders.

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Preeclampsia Diagnostics Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Preeclampsia Diagnostics Industry Impact

Chapter 2 Global Preeclampsia Diagnostics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Preeclampsia Diagnostics (Volume and Value) by Type
2.3 Global Preeclampsia Diagnostics (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Preeclampsia Diagnostics Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Preeclampsia Diagnostics Market Analysis
Chapter 6 East Asia Preeclampsia Diagnostics Market Analysis
Chapter 7 Europe Preeclampsia Diagnostics Market Analysis
Chapter 8 South Asia Preeclampsia Diagnostics Market Analysis
Chapter 9 Southeast Asia Preeclampsia Diagnostics Market Analysis
Chapter 10 Middle East Preeclampsia Diagnostics Market Analysis
Chapter 11 Africa Preeclampsia Diagnostics Market Analysis
Chapter 12 Oceania Preeclampsia Diagnostics Market Analysis
Chapter 13 South America Preeclampsia Diagnostics Market Analysis
Chapter 14 Company Profiles and Key Figures in Preeclampsia Diagnostics Business
Chapter 15 Global Preeclampsia Diagnostics Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology